Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF inhibitor
Pharma
After 3 CRLs, FDA approves Outlook's AMD drug Lytenava
The FDA has approved Outlook's Lytenava for wet age-related macular degeneration. The compound has been used off-label in the indication for two decades.
Kevin Dunleavy
Jul 27, 2026 11:51am
Outlook stock plummets as FDA again snubs wet AMD drug
Aug 28, 2025 10:55am
Regeneron's Eylea franchise stumbles on several fronts in Q1
Apr 29, 2025 2:50pm
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Oct 9, 2024 11:47am
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Sep 8, 2024 11:30am
Merck CMO talks Akeso, Summit's Keytruda head-to-head win
Jun 3, 2024 12:00pm
